Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.41 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177893 | 0.89 | MAP4K4 (0.46) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4178328 | 0.88 | CYP1A2 (0.43) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4183733 | 0.84 | MAP4K4 (0.60) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4185137 | 0.82 | IRAK4 (0.47) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4176710 | 0.81 | MAP4K4 (0.58) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4174439 | 0.80 | MAP4K4 (0.60) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| Hydrochloric Acid SCHEMBL4182954 | 0.80 | MAP4K4 (0.58) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4173788 | 0.79 | CYP1A2 (0.43) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4169484 | 0.78 | IRAK4 (0.59) | MAP4K4CYP1A2CLK4USP2CYP2C19 | |
| SCHEMBL4175433 | 0.78 | MAPK1 (0.36) | MAP4K4CYP1A2CLK4USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | claimed |
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRUENENTHAL GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1996562-A1 | SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007104560-A1 | SUBSTITUTED 4-AMINO-QUINAZOLINE DERIVATIVES AS REGULATORS OF METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069320-A1 | Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof | GRM1, GRIN1, GRM2 | MAP4K4 1662/4885CYP1A2 4353/4885CLK4 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.